Enabling the Advancement of Healthcare and Consumer Products.

Wilson Sonsini's regulatory team advises clients on food and drug law and policy governing healthcare and consumer products.

Wilson Sonsini Goodrich & Rosati's legacy closely traces the birth and evolution of Silicon Valley.

For nearly six decades, Wilson Sonsini has represented the technology pioneers associated with virtually every milestone innovation.

Today, the firm is synonymous with ushering promising, innovative companies through their business life cycle.

Read More About Us

Quick Links

April 7, 2020
Live Webinar Navigating Down Round Financings

Click here to register or for more info

Careers

We look for the best and brightest of tomorrow and develop careers from the ground up.

News and Featured Insights

Alerts

CARES Act Contains Significant New Over-The-Counter (OTC) Drug Provisions

Newsletters

Digital Health Report: Q1 2020

Alerts

The CARES Act: A Summary for Technology and Life Sciences Companies

Leading Matters

Client Highlights

Firm Advises Investors in iTeos Therapeutics’ $125 Million B2 Financing

On April 1, 2020, iTeos Therapeutics, a privately-held clinical-stage biotech company developing innovative cancer immunotherapies, announced the closing of an oversubscribed Series B2 financing, which raised a total of $125 million. The Series B2 financing round was co-led by RA Capital Management and Boxer Capital, and included new investors Janus Henderson Investors, RTW Investments, and Invus along with existing investors MPM Capital, HBM Partners, 6 Dimensions Capital, Curative Ventures, Fund+, VIVES Louvain Technology Fund, SRIW, and SFPI. The company, which is based in Belgium with a U.S. headquarters in Cambridge, will use the money to run clinical trials of its two lead cancer drugs. One of those treatments, EOS-850, will be tested in combination with Merck & Co.’s blockbuster drug Keytruda. The cancer immunotherapy made Merck more than $11 billion in worldwide sales last year.

Learn More

Client Highlights

Firm Advises SanBio in Alliance with Ocumension

On March 31, 2020, SanBio, Co. announced that it had entered into a development and commercialization alliance with Ocumension (Hong Kong) Limited. Wilson Sonsini Goodrich & Rosati advised SanBio in the agreement.

Learn More

Client Highlights

Firm Advises CloudGenix in Sale to Palo Alto Networks

On March 31, 2020, Palo Alto Networks, a global leader in cybersecurity, announced that it has entered into a definitive agreement to acquire CloudGenix, a provider of cloud-delivered SD-WAN. Wilson Sonsini Goodrich & Rosati advised CloudGenix in the agreement.

Learn More

Client Highlights

Wilson Sonsini Acts as Antitrust Counsel to Deutsche Telekom on Historic Merger Between T-Mobile and Sprint

On April 1, T-Mobile announced that it has officially completed its merger with Sprint Corporation. Wilson Sonsini Goodrich & Rosati served as lead antitrust counsel to Deutsche Telekom, T-Mobile’s parent company, in the matter.

Learn More

Client Highlights

Firm Advises TranscripTx and ReCode Therapeutics in Merger and Oversubscribed $80 Million Series A Fundraising

On March 26, 2020, ReCode Therapeutics, Inc. announced the completion of an all-stock merger with TranscripTx, Inc and, immediately thereafter, the closing of an oversubscribed $80 million Series A financing round. OrbiMed Advisors LLC and Colt Ventures co-led the round, with participation from MPM Capital, Vida Ventures LLC, Hunt Technology Ventures, L.P., and Osage University Partners. ReCode will use the proceeds to continue the preclinical development of its lead programs in primary ciliary dyskinesia and cystic fibrosis. The company expects to file an Investigational New Drug Application for both programs in 2021. In addition, ReCode will advance its proprietary non-viral lipid nanoparticle delivery platform for organ-specific delivery of RNA therapies and gene editing components.

Learn More

Client Highlights

Wilson Sonsini Advises Real in Launch of Digital Mental Health Offerings

On March 26, 2020, Real, a membership-based organization offering therapy and mental health resources for female-identifying people in New York, launched a virtual version of its soon-to-be-opened mental health studio. Wilson Sonsini Goodrich & Rosati advised Real in this effort.

Learn More

See More Leading Matters

Digital Health Report

During this unprecedented time, digital health is disrupting our healthcare delivery system for the better. Digital health companies are working hard to provide innovative telehealth, digital screening, and testing services. They are leveraging AI to assess symptoms, model outcomes, and identify possible treatments for COVID-19. Digital health companies are providing physicians and other frontline responders with new tools to fight this pandemic.